The impact of additive or substitutive clinical study design on the negotiated reimbursement for oncology pharmaceuticals after early benefit assessment in Germany

Table 5 Tests for normality

Dependent Variable	Shapiro-Wilk Statistic W	Critical value of W^a	P-value
Additive premiums	0.918318	0.868535	0.238
Multiplicative premiums	0.584712	0.868535	0.000048*
Transformed dependent variable
Log additive premiums	0.945428	0.868535	0.531
Log multiplicative premiums	0.762327	0.868535	0.0025*
Metric independent Variable
EU Prices	0.588874	0.868535	0.000053*
Comparable drugs	0.907858	0.868535	0.171
AnTC ACT	0.817607	0.868535	0.011
Target population	0.772696	0.868535	0.0033*

ISSN: 2191-1991